SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Progen Industries Ltd (PGLAF)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Henrik11/1/2007 2:33:38 PM
   of 349
 
Thursday, 1 November 2007 -
PGL.AX closed up 10% @ A$2.86 (US$2.67)

Headline from the Australian Financial Review; "Street Talk"

Takeover talk takes over

Over in the biotech world it is still a far harder slog, with liver cancer drug developer Progen Pharmaceuticals losing a key supporter this week after AMP Capital Investors revealed it had ceased to be a substantial shareholder.

This is said to be a result of recent changes to AMP’s investment team.

Coincidentally, Northcape Capital, which has employed the departed AMP fund manager responsible for the holding (though he is yet to actually start) has emerged in recent days as a substantial shareholder in Progen, so it looks like the boutique fund manager is filling the void left by AMP.

Unfortunately Progen shares are now trading at $2.60, way back from the $5.74 price at which the company raised money in June and Progen’s price of more than $7 a share in May.

Investors are waiting for some newsflow with regards to a deal with a big pharmaceutical company, while clearly some aren’t going to be too happy if the price remains at current levels by the time the annual meeting comes around at the end of this month.

There has also been talk that shareholders are agitating for someone to buy the company (perhaps an Asian pharmaceuticals group), but maybe the situation will become clearer over the next month. Encouraging progress on Progen’s PI-88 drug made it on of the more closely followed biotechs by institutional investors (though not many are), but it looks as though that momentum has been lost.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News